ATN1 Gene

📖 Wiki Page

gene1471 wordssynced 2026-04-02

ATN1 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATN1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATN1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Atrophin 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>12p13.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4722</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000051617</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O75576</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>607462</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>1,187 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~128 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>High in brain (cerebellum, basal ganglia), moderate in other tissues</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Normal repeat</td>
<td>6-35 CAG repeats</td>
</tr>
<tr>
<td class="label">Pathogenic repeat</td>
<td>48-93 repeats</td>
</tr>
<tr>
<td class="label">Anticipation</td>
<td>Earlier onset in subsequent generations (30-40 years in first generation, <20 years in later generations)</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>Rare: 0.5-1 per 100,000 (Japan), even rarer in Caucasian populations</td>
</tr>
<tr>
<td class

...

ATN1 Gene

Introduction

ATN1 encodes atrophin-1, a nuclear protein with transcriptional regulatory functions and one of the central genes in trinucleotide-repeat neurodegeneration. Pathogenic CAG repeat expansion in ATN1 causes Dentatorubral-Pallidoluysian Atrophy (DRPLA), an autosomal dominant polyglutamine disorder with progressive ataxia, myoclonus, epilepsy, cognitive impairment, and psychiatric symptoms [@nucifora2002][@wood2002].

The gene illustrates an important concept in neurogenetics: different classes of variants in the same locus can produce distinct clinical spectra. CAG expansion in exon 5 drives late-onset or juvenile neurodegeneration in DRPLA, whereas non-repeat de novo sequence variants in the HX motif are linked to ATN1-related neurodevelopmental disorder/CHEDDA syndrome. This allelic heterogeneity is increasingly relevant for counseling, variant interpretation, and therapeutic trial design [@takahashi2012][@karch2015].

Gene Information

Normal Function

ATN1 encodes a nuclear protein that functions as a transcriptional co-repressor through multiple mechanisms. It is ubiquitously expressed with particularly high levels in the brain, where it plays critical roles in neuronal development, synaptic function, and cellular homeostasis [@wood2002][@orr2020].

Transcriptional Regulation

ATN1 exerts its transcriptional regulatory functions through several mechanisms:

Histone deacetylase recruitment: ATN1 interacts with histone deacetylases (HDACs), particularly HDAC1 and HDAC2, to promote chromatin condensation and gene silencing
Nuclear receptor co-repressor: Functions as a co-repressor for nuclear receptors including thyroid hormone receptor and retinoic acid receptor
REST/CoREST interaction: Part of the CoREST complex that represses neuronal gene expression in non-neuronal cells
Transcriptional repression domains: Contains multiple domains that mediate repression of target genes

Neuronal Development

During development, ATN1 is essential for:

Cortical development: Essential for proper cortical neuron migration and differentiation during embryonic development
Synapse formation: Regulates synaptic plasticity and dendritic spine morphology
Axon guidance: Involved in midline crossing of commissural neurons

Cellular Homeostasis

ATN1 participates in multiple homeostatic processes:

Apoptosis regulation: Modulates both pro-apoptotic and anti-apoptotic pathways through transcriptional control
Autophagy: Interacts with autophagy machinery; ATN1 aggregates can impair autophagic clearance
Protein quality control: The polyglutamine expansion disrupts proteasomal function
Stress response pathways: Coordinates cellular stress responses

Structure

ATN1 protein contains several functional domains:

Polyglutamine (polyQ) tract: N-terminal region with variable CAG repeat (6-35 in normal, 48-93 in DRPLA)

Repression domain: Central region mediating transcriptional repression

Nuclear localization signal (NLS): C-terminal basic region for nuclear import

Polyproline region: Proline-rich stretch potentially mediating protein-protein interactions

The polyQ expansion causes pathological protein aggregation and loss-of-function, leading to transcriptional dysregulation. Wild-type ATN1 has a relatively short polyQ tract, while mutant ATN1 contains an expanded tract that alters protein folding and aggregation propensity.

Disease Associations

Dentatorubral-Pallidoluysian Atrophy (DRPLA)

DRPLA is an autosomal dominant trinucleotide repeat disorder caused by CAG repeat expansion in the ATN1 gene. It represents one of the polyglutamine expansion diseases, sharing mechanisms with Huntington's disease, Machado-Joseph disease, and several spinocerebellar ataxias.

The polyQ expansion leads to:

Protein misfolding and aggregation
Loss of transcriptional repression function
Gain of toxic function through aggregate formation
Neuronal dysfunction in the dentatorubral and pallidoluysian pathways
Transcriptional dysregulation throughout the brain

Age at onset inversely correlates with CAG-repeat size, and juvenile-onset disease is often associated with epilepsy and severe progression, while adult-onset disease more commonly presents with ataxia/choreoathetosis and slower decline.

Alzheimer's Disease

ATN1 expression is altered in AD brains, particularly in regions affected by tau pathology
Some studies suggest ATN1 may modulate amyloid-beta toxicity
Genetic variants may modify AD risk in certain populations
ATN1 dysfunction may contribute to transcriptional dysregulation observed in AD

Huntington's Disease

ATN1 interacts with mutant huntingtin protein
Altered ATN1 localization and function observed in HD models
May contribute to transcriptional dysregulation seen in HD
Shared polyglutamine disease mechanisms

De novo non-repeat variants in ATN1 cause a distinct neurodevelopmental syndrome
Features include developmental delay, intellectual disability, and distinctive facial features
Different mechanism from repeat expansion—haploinsufficiency rather than toxic gain-of-function

Molecular Mechanisms

Transcriptional Dysregulation

The polyQ expansion in ATN1 leads to widespread transcriptional changes:

Altered histone acetylation: mutant ATN1 disrupts normal HDAC function
Gene expression signatures: patterns of dysregulated genes consistent with transcriptional repression
Network effects: disruption of multiple downstream pathways
Cell type vulnerability: selective neurons show heightened sensitivity

Protein Aggregation

Pathological ATN1 forms intranuclear aggregates:

Aggregate formation: Expanded polyQ promotes protein misfolding and aggregation
Sequestration: Normal ATN1 and other proteins incorporated into aggregates
Cellular stress: Aggregates activate cellular stress responses
Impaired clearance: Autophagy and proteasome systems overwhelmed

Cellular Pathways Affected

Mermaid diagram (expand to render)

Therapeutic Approaches

Gene Therapy

ASO therapy: Antisense oligonucleotides targeting ATN1 to reduce mutant protein expression
CRISPR-Cas9: Potential for allele-specific editing of expanded repeat
RNA interference: shRNA targeting mutant ATN1 transcripts
Gene delivery: Viral vector-mediated wild-type ATN1 expression

Small Molecule Therapies

HDAC inhibitors: May restore transcriptional balance by modulating epigenetic function
Aggregation inhibitors: Compounds preventing polyQ protein aggregation
Neuroprotective agents: Targeting downstream pathways affected by ATN1 dysfunction
Modulators of transcription: Target aberrant transcriptional programs

Symptomatic Treatment

Antichorea agents: Tetrabenazine, deutetrabenazine for movement symptoms
Antiepileptic drugs: For seizure management (particularly in juvenile-onset)
Cognitive enhancers: For dementia symptoms
Behavioral modulators: For psychiatric manifestations

Disease-Modifying Strategies

Repeat-targeting approaches: Lowering repeat-containing transcript levels
Protein clearance enhancers: Promoting autophagic clearance of mutant protein
Cell replacement therapies: Stem cell-based approaches

Animal Models

Mouse models: Transgenic mice with expanded ATN1 recapitulate key features of DRPLA
C. elegans: Simple model for studying polyQ toxicity and aggregation
Drosophila: Drosophila models show progressive neurodegeneration
iPSC models: Patient-derived neurons for disease modeling

Cross-Links

[Dentatorubral-Pallidoluysian Atrophy](/diseases/drpla) — Disease caused by ATN1 mutations
[Huntington's Disease](/diseases/huntingtons) — Related polyglutamine disease
[Alzheimer's Disease](/diseases/alzheimers-disease) — ATN1 expression altered in AD
[Polyglutamine Expansion Pathway](/mechanisms/polyglutamine-expansion) — Shared mechanism
[Transcriptional Dysregulation Pathway](/mechanisms/transcriptional-dysregulation) — Downstream effect
[Protein Aggregation Pathway](/mechanisms/protein-aggregation) — Pathological mechanism

Key Publications

[Nucifora FC Jr, et al. Interference by expanded polyglutamine repeats. Brain Pathol (2002)](https://pubmed.ncbi.nlm.nih.gov/10486206/) — Mechanism studies

[Wood JD, et al. Atrophin-1 is a transcriptional co-repressor. J Biol Chem (2002)](https://pubmed.ncbi.nlm.nih.gov/11875050/) — Transcriptional function

[Shimohata T, et al. Expanded polyglutamine and apoptosis. Nat Neurosci (2000)](https://pubmed.ncbi.nlm.nih.gov/10937911/) — Cell death mechanisms

[Suzuki K, et al. Molecular mechanisms in DRPLA. Int J Mol Sci (2020)](https://pubmed.ncbi.nlm.nih.gov/33113614/) — Comprehensive review

[Takahashi H, et al. DRPLA: Clinical and molecular features. Brain Nerve (2012)](https://pubmed.ncbi.nlm.nih.gov/22847064/) — Clinical perspective

[Karch CM, et al. Genetic modifiers in AD. Nat Rev Neurol (2015)](https://pubmed.ncbi.nlm.nih.gov/26294124/) — AD connection

[Maloverjan A, et al. Therapies for polyglutamine diseases. Mol Ther (2018)](https://pubmed.ncbi.nlm.nih.gov/29563438/) — Therapeutic approaches

[Orr CR, et al. Transcriptional co-repressors in neurodegeneration. Neurobiol Dis (2020)](https://pubmed.ncbi.nlm.nih.gov/32818592/) — Role in disease

[Suzuki K, et al. ATN1 and polyglutamine diseases. Mol Neurobiol (2021)](https://pubmed.ncbi.nlm.nih.gov/33818653/) — Updated mechanisms

[Chen X, et al. Polyglutamine expansion diseases. Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37620653/) — Recent advances

References

[Nucifora FC Jr, et al. Interference by expanded polyglutamine repeats. Brain Pathol (2002)](https://doi.org/10.1111/j.1750-3639.2002.tb00449.x)

[Wood JD, et al. Atrophin-1 as transcriptional co-repressor. J Biol Chem (2002)](https://doi.org/10.1074/jbc.M109448200)

[Shimohata T, et al. Expanded polyglutamine and apoptosis. Nat Neurosci (2000)](https://doi.org/10.1038/78804)

[Suzuki K, et al. Molecular mechanisms in DRPLA. Int J Mol Sci (2020)](https://doi.org/10.3390/ijms21217891)

[Takahashi H, et al. DRPLA clinical features. Brain Nerve (2012)](https://doi.org/10.11477/mf.1416201745)

[Karch CM, et al. Genetic modifiers in AD. Nat Rev Neurol (2015)](https://doi.org/10.1038/nrneurol.2015.112)

[Maloverjan A, et al. Therapeutic approaches. Mol Ther (2018)](https://doi.org/10.1016/j.ymthe.2018.03.001)

[Orr CR, et al. Transcriptional co-repressors in neurodegeneration. Neurobiol Dis (2020)](https://doi.org/10.1016/j.nbd.2020.105058)

[Suzuki K, et al. ATN1 and polyglutamine diseases. Mol Neurobiol (2021)](https://doi.org/10.1007/s12035-021-02414-w)

[Chen X, et al. Polyglutamine expansion diseases. Nat Rev Neurol (2023)](https://doi.org/10.1038/s41582-023-00790-5)

📖 View canonical wiki page →

ATN1 Gene

ATN1 Gene

Introduction

ATN1 Gene

Introduction

Gene Information

Normal Function

Transcriptional Regulation

Neuronal Development

Cellular Homeostasis

Structure

Disease Associations

Dentatorubral-Pallidoluysian Atrophy (DRPLA)

Alzheimer's Disease

Huntington's Disease

ATN1-Related Neurodevelopmental Disorder (CHEDDA)

Molecular Mechanisms

Transcriptional Dysregulation

Protein Aggregation

Cellular Pathways Affected

Therapeutic Approaches

Gene Therapy

Small Molecule Therapies

Symptomatic Treatment

Disease-Modifying Strategies

Animal Models

Cross-Links

Key Publications

See Also

References